Results 11 to 20 of about 28,823 (297)

Effects of Combination Treatment With Dipeptidyl Peptidase IV Inhibitor and Sulfonylurea on Glucose Levels in Rats [PDF]

Journal of Pharmacological Sciences, 2004
The effects of orally administered dipeptidyl peptidase IV (DPP-IV) inhibitor on the glucose-lowering effect of glibenclamide are still unknown. We evaluated the effects of combination treatment with a long-lasting DPP-IV inhibitor, K579 ((S)-1-[4-methyl-
Kotaro Takasaki, Takao Nakajima, Kimihisa Ueno, Yuji Nomoto, Katsuya Higo   +4 more
doaj   +2 more sources

Novel Dipeptidyl Peptidase-4–Inhibiting Peptide Derived From β-Lactoglobulin [PDF]

Journal of Pharmacological Sciences, 2011
.: Trypsin-treated β-lactoglobulin significantly decreased the glucose level after an oral glucose tolerance test using mice. We performed the present study to identify the active peptide inhibiting dipeptidyl peptidase-4 from trypsin-treated β ...
Masayuki Uchida, Yukio Ohshiba, Orie Mogami   +2 more
doaj   +2 more sources

Serum and Adipose Dipeptidyl Peptidase 4 in Cardiovascular Surgery Patients: Influence of Dipeptidyl Peptidase 4 Inhibitors [PDF]

Journal of Clinical Medicine, 2022
Dipeptidyl peptidase 4 (DPP-4) is a novel adipokine and may be involved in the association between adipose tissue and metabolic syndrome. We investigated DPP-4 and adiponectin levels in the serum, subcutaneous adipose tissue (SAT), and epicardial adipose tissue (EAT), and their relationship with preoperative factors, as well as comparing the DPP-4 ...
Ikuko Shibasaki, Toshiaki Nakajima, Taira Fukuda, Takaaki Hasegawa, Hironaga Ogawa, Go Tsuchiya, Yusuke Takei, Masahiro Tezuka, Takashi Kato, Yuta Kanazawa, Yasuyuki Kano, Toshiyuki Kuwata, Motoshi Ouchi, Shigeru Toyoda, Yoshimasa Aso, Hirotsugu Fukuda   +15 more
openaire   +3 more sources

A dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, attenuates cardiac dysfunction after myocardial infarction independently of DPP-4 [PDF]

Journal of Pharmacological Sciences, 2019
Dipeptidyl peptidase-4 (DPP-4) inhibitors not only improve impaired glucose tolerance in diabetes, but also have pleiotropic extra-pancreatic effects such as preconditioning effect for myocardial ischemia-reperfusion injury.
Takehiro Yamaguchi, Ayano Watanabe, Masako Tanaka, Masayuki Shiota, Mayuko Osada-Oka, Soichi Sano, Minoru Yoshiyama, Katsuyuki Miura, Shojiro Kitajima, Shinji Matsunaga, Shuhei Tomita, Hiroshi Iwao, Yasukatsu Izumi   +12 more
doaj   +2 more sources

Significance of Vascular Dipeptidyl Peptidase-4 Inhibition on Vascular Protection in Zucker Diabetic Fatty Rats [PDF]

Journal of Pharmacological Sciences, 2014
.: To clarify the role of dipeptidyl peptidase-4 (DPP-4) inhibition in vascular tissues, we compared the effects of the poorly tissue-penetrative DPP-4 inhibitor sitagliptin to the highly tissue-penetrative DPP-4 inhibitor linagliptin in Zucker diabetic ...
Shinji Takai, Hiroshi Sakonjo, Denan Jin
doaj   +2 more sources

Dipeptidyl Peptidase 4 Inhibitors Decrease the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis C Infection and Type 2 Diabetes Mellitus: A Nationwide Study in Taiwan

Frontiers in Public Health, 2021
Introduction: Dipeptidyl peptidase 4 inhibitors (DPP-4 inhibitors) are incretin-based oral antidiabetic drugs. Previous studies have shown an association between increased plasma activity of DPP-4 and chronic hepatitis C virus (HCV) infection. Dipeptidyl
Wei-Hao Hsu, Wei-Hao Hsu, Shu-Ping Sue, Shu-Ping Sue, Hsiu-Ling Liang, Hsiu-Ling Liang, Chin-Wei Tseng, Chin-Wei Tseng, Hsiu-Chu Lin, Hsiu-Chu Lin, Wei-Lun Wen, Wei-Lun Wen, Mei-Yueh Lee, Mei-Yueh Lee   +13 more
doaj   +1 more source

Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin [PDF]

Diabetes & Metabolism Journal, 2016
BackgroundWe compared the efficacies of vildagliptin (50 mg twice daily) relative to pioglitazone (15 mg once daily) as an add-on treatment to metformin for reducing glycosylated hemoglobin (HbA1c) levels in Korean patients with type 2 diabetes ...
Jong Ho Kim, Sang Soo Kim, Hong Sun Baek, In Kyu Lee, Dong Jin Chung, Ho Sang Sohn, Hak Yeon Bae, Mi Kyung Kim, Jeong Hyun Park, Young Sik Choi, Young Il Kim, Jong Ryeal Hahm, Chang Won Lee, Sung Rae Jo, Mi Kyung Park, Kwang Jae Lee, In Joo Kim   +16 more
doaj   +1 more source

The effect of sitagliptin on hepatic ischemic reperfusion injury in rats

Medical Journal of Dr. D.Y. Patil Vidyapeeth, 2020
Background: Dipeptidyl peptidase-4 (DPP4, DPPIV, CD26, EC 3.4.14.5) was found out more than four decades ago as a serine protease that severs N-terminal dipeptides from peptide substrates. DPP-4 inhibitors have been used in many animal models of lung and
Song-Chol Mun, Hye-Sun Hong
doaj   +1 more source

SARS-CoV-2 and diabetes: A potential therapeutic effect of dipeptidyl peptidase 4 inhibitors in diabetic patients diagnosed with COVID-19

Metabolism Open, 2021
COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 and has become an urgent economic and health challenge. Dipeptidyl peptidase 4 (DPP4), also mentioned as a cluster of differentiation 26 (CD26) is a serine exopeptidase found in two ...
Zemene Demelash Kifle, Alem Endeshaw Woldeyohanin, Chilot Abiyu Demeke   +2 more
doaj   +1 more source

Comparing treatment intensification and clinical outcomes of metformin and dipeptidyl peptidase‐4 inhibitors in treatment‐naïve patients with type 2 diabetes in Japan

Journal of Diabetes Investigation, 2020
Japan's guidelines emphasize tailored therapy, but do not guide physicians on the use of a specific regimen in drug‐naive patients. The role of long‐term initial therapy could be important in key elements of diabetes treatment, such as continuation of ...
Takeshi Horii, Makiko Iwasawa, Jyunichi Shimizu, Koichiro Atsuda   +3 more
doaj   +1 more source